The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

This includes large pharmacy chains and pharmacy benefit managers, leading to abuses that undermine patient benefits. Also ...

Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

but J&J in August proposed a plan that would require disproportionate share hospitals to buy its blood thinner drug Xarelto ...

The company filed a lawsuit asking for a federal court’s permission to change when it gives lucrative drug discounts to ...

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive ...

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

Selarsdi (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab), is expanded to the indications to include treatment of Crohn disease.

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...